2,442 Shares in TransMedics Group, Inc. $TMDX Purchased by Atria Wealth Solutions Inc.

Key Points

• Atria Wealth Solutions Inc. acquired 2,442 shares of TransMedics Group, Inc., valued at approximately $316,000, in the second quarter.
• TransMedics Group has a consensus rating of "Moderate Buy" from analysts, with price targets ranging between $123.00 and $145.00.
• In its latest quarterly earnings, TransMedics reported an EPS of $0.92, significantly beating analysts' estimates, and noted a 37.7% year-over-year revenue increase.

Atria Wealth Solutions Inc. acquired a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 2,442 shares of the company's stock, valued at approximately $316,000.

Other hedge funds have also modified their holdings of the company. Opal Wealth Advisors LLC bought a new position in shares of TransMedics Group during the second quarter worth about $26,000. Smartleaf Asset Management LLC grew its holdings in shares of TransMedics Group by 44.3% during the first quarter. Smartleaf Asset Management LLC now owns 440 shares of the company's stock worth $30,000 after buying an additional 135 shares in the last quarter. Quarry LP grew its holdings in shares of TransMedics Group by 88.5% during the first quarter. Quarry LP now owns 592 shares of the company's stock worth $40,000 after buying an additional 278 shares in the last quarter. Sound Income Strategies LLC bought a new position in shares of TransMedics Group during the second quarter worth about $48,000. Finally, Hager Investment Management Services LLC grew its holdings in shares of TransMedics Group by 38.3% during the first quarter. Hager Investment Management Services LLC now owns 740 shares of the company's stock worth $50,000 after buying an additional 205 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on TMDX. Canaccord Genuity Group reiterated a "buy" rating and set a $142.00 price objective on shares of TransMedics Group in a report on Tuesday, October 14th. Wall Street Zen upgraded TransMedics Group from a "hold" rating to a "buy" rating in a report on Saturday. Morgan Stanley raised their price target on TransMedics Group from $115.00 to $123.00 and gave the company an "equal weight" rating in a research note on Friday, August 1st. Weiss Ratings restated a "hold (c)" rating on shares of TransMedics Group in a research note on Wednesday, October 8th. Finally, Jefferies Financial Group assumed coverage on TransMedics Group in a research note on Monday, October 13th. They issued a "buy" rating and a $145.00 price target for the company. Seven research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $127.18.

TransMedics Group Stock Performance

TMDX opened at $120.13 on Wednesday. TransMedics Group, Inc. has a 12-month low of $55.00 and a 12-month high of $145.50. The stock has a market cap of $4.10 billion, a price-to-earnings ratio of 62.24 and a beta of 2.08. The business has a 50 day moving average of $116.15 and a 200-day moving average of $114.35. The company has a quick ratio of 9.17, a current ratio of 9.86 and a debt-to-equity ratio of 1.61.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The company reported $0.92 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.48 by $0.44. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%.The company had revenue of $157.37 million during the quarter, compared to analysts' expectations of $146.64 million. During the same period last year, the firm posted $0.35 earnings per share. The business's revenue was up 37.7% on a year-over-year basis. TransMedics Group has set its FY 2025 guidance at EPS. On average, equities research analysts expect that TransMedics Group, Inc. will post 1 earnings per share for the current year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Want to see what other hedge funds are holding TMDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group, Inc. (NASDAQ:TMDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.